Studies of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, can provide insight into important tumorigenic pathways. As altered methylation often activates or silences genes, changes in the epigenome can affect gene expression and the rate of cancer progression.
Next-generation sequencing (NGS) and microarray technologies can detect altered methylation patterns and other epigenetic changes in cancer. Illumina works with cancer epigenetics experts to ensure its NGS and array solutions meet the field's rapidly evolving needs.
Aberrant methylation is a common epigenetic alteration in cancer. Methylation analysis with NGS enables researchers to identify and track cancer methylation patterns by sequencing the methylated genome.Learn More About Methylation Sequencing
Methylation arrays enable epigenome-wide association studies that can analyze multiple cancer samples in parallel. Arrays quantitatively interrogate methylation sites across the genome, providing researchers with insight into the regulation of cancer-related genes and pathways.Learn More About Methylation Arrays
Learn why Se Hoon Kim, MD, PhD believes that combining NGS with methylation arrays can deliver value in somatic mutation profiling and tumor characterization.Read Interview
Altered transcription factor binding is a common epigenetic pattern in cancer. Chromatin immunoprecipitation sequencing (ChIP-Seq) experiments provide a complete snapshot of DNA regions associated with a protein of interest.Learn More About ChIP-Seq
Researchers use an Illumina methylation array on tumor and PBLs to identify differences in breast tumor development between African American and non-African American women.Read Publication
A methylation fingerprint is used to stratify medulloblastoma subgroups for improved characterization.Read Publication
A review of recent epigenetic discoveries in prostate cancer, highlighting their potential as biomarkers for diagnosis, segmentation, and monitoring.Read Publication